(PHR) Phreesia - Overview
Sector: Healthcare | Industry: Health Information Services | Exchange: NYSE (USA) | Market Cap: 584m USD | Total Return: -62.6% in 12m
Avg Turnover: 13.6M
Qual. Beats: 0
Rev. Trend: 99.5%
Qual. Beats: 1
Warnings
Altman Z'' -1.38 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
Phreesia, Inc. (PHR) operates a specialized software-as-a-service (SaaS) platform designed to automate patient intake and financial workflows for healthcare providers in the United States and Canada. The company’s suite includes AI-enabled appointment scheduling, referral management, and automated patient communication tools. Beyond software, Phreesia provides physical hardware, such as self-service kiosks and tablets, to facilitate on-site data capture and clinical documentation.
The business model relies on a dual-revenue stream consisting of subscription fees from healthcare organizations and transaction-based fees from its integrated payment processing solutions. In the Health Care Technology sector, high switching costs often provide established SaaS providers with significant client retention, as clinical data integration is complex to replicate. Phreesia serves a diverse client base ranging from ambulatory practices and large health systems to life sciences companies and government entities.
Investors can evaluate the long-term sustainability of these revenue streams by reviewing the fundamental data on ValueRay. Founded in 2005 and headquartered in Delaware, the company focuses on accelerating cash collections for providers while streamlining the digital patient experience.
- Life sciences engagement revenue growth drives high-margin subscription and media scalability
- Patient payment volume expansion accelerates recurring transaction processing fee income
- Operating leverage and cost discipline determine path to consistent GAAP profitability
- Increasing healthcare provider network density enhances long-term upsell and cross-sell potential
- Regulatory changes in data privacy impact pharmaceutical advertising and patient outreach efficacy
| Net Income: 12.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 5.04 > 1.0 |
| NWC/Revenue: 23.24% < 20% (prev 24.09%; Δ -0.86% < -1%) |
| CFO/TA 0.13 > 3% & CFO 87.9m > Net Income 12.7m |
| Net Debt (34.3m) to EBITDA (44.1m): 0.78 < 3 |
| Current Ratio: 1.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.0m) vs 12m ago 5.30% < -2% |
| Gross Margin: 66.56% > 18% (prev 68.02%; Δ -1.46% > 0.5%) |
| Asset Turnover: 92.93% > 50% (prev 108.5%; Δ -15.59% > 0%) |
| Interest Coverage Ratio: 1.43 > 6 (EBIT TTM 12.6m / Interest Expense TTM 8.82m) |
| A: 0.17 (Total Current Assets 267.3m - Total Current Liabilities 152.1m) / Total Assets 666.1m |
| B: -1.20 (Retained Earnings -796.2m / Total Assets 666.1m) |
| C: 0.02 (EBIT TTM 12.6m / Avg Total Assets 533.3m) |
| D: 1.17 (Book Value of Equity 359.1m / Total Liabilities 307.1m) |
| Altman-Z'' = -1.38 = CCC |
| DSRI: 0.73 (Receivables 90.3m/108.1m, Revenue 495.6m/434.5m) |
| GMI: 1.02 (GM 68.02% / 66.56%) |
| AQI: 1.41 (AQ_t 0.56 / AQ_t-1 0.40) |
| SGI: 1.14 (Revenue 495.6m / 434.5m) |
| TATA: -0.11 (NI 12.7m - CFO 87.9m) / TA 666.1m) |
| Beneish M = -2.90 (Cap -4..+1) = A |
As of June 04, 2026, the stock is trading at USD 9.65 with a total of 1,144,384 shares traded.
Over the past week, the price has changed by +5.70%,
over one month by -0.21%,
over three months by -21.99% and
over the past year by -62.57%.
Phreesia has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy PHR.
- StrongBuy: 10
- Buy: 5
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14.3 | 48% |
P/E Trailing = 59.0625
P/E Forward = 17.1821
P/S = 1.2147
P/B = 1.6257
Revenue TTM = 495.6m USD
EBIT TTM = 12.6m USD
EBITDA TTM = 44.1m USD
Long Term Debt = 90.0m USD (from longTermDebt, last fiscal year)
Short Term Debt = 9.22m USD (from shortTermDebt, last fiscal year)
Debt = 109.0m USD (corrected: LT Debt 90.0m + ST Debt 9.22m) + Leases 9.79m
Net Debt = 34.3m USD (calculated: Debt 109.0m - CCE 74.7m)
Enterprise Value = 618.1m USD (583.8m + Debt 109.0m - CCE 74.7m)
Interest Coverage Ratio = 1.43 (Ebit TTM 12.6m / Interest Expense TTM 8.82m)
EV/FCF = 8.13x (Enterprise Value 618.1m / FCF TTM 76.0m)
FCF Yield = 12.29% (FCF TTM 76.0m / Enterprise Value 618.1m)
FCF Margin = 15.33% (FCF TTM 76.0m / Revenue TTM 495.6m)
Net Margin = 2.56% (Net Income TTM 12.7m / Revenue TTM 495.6m)
Gross Margin = 66.56% ((Revenue TTM 495.6m - Cost of Revenue TTM 165.7m) / Revenue TTM)
Gross Margin QoQ = 86.51% (prev 43.01%)
Tobins Q-Ratio = 0.93 (Enterprise Value 618.1m / Total Assets 666.1m)
Interest Expense / Debt = 8.09% (Interest Expense 8.82m / Debt 109.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 9.99m (EBIT 12.6m * (1 - 21.00%))
Current Ratio = 1.76 (Total Current Assets 267.3m / Total Current Liabilities 152.1m)
Debt / Equity = 0.30 (Debt 109.0m / totalStockholderEquity, last quarter 359.1m)
Debt / EBITDA = 0.78 (Net Debt 34.3m / EBITDA 44.1m)
Debt / FCF = 0.45 (Net Debt 34.3m / FCF TTM 76.0m)
Total Stockholder Equity = 328.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.38% (Net Income 12.7m / Total Assets 666.1m)
RoE = 3.87% (Net Income TTM 12.7m / Total Stockholder Equity 328.7m)
RoCE = 3.02% (EBIT 12.6m / Capital Employed (Equity 328.7m + L.T.Debt 90.0m))
RoIC = 2.00% (NOPAT 9.99m / Invested Capital 498.5m)
WACC = 11.02% (E(583.8m)/V(692.8m) * Re(11.89%) + D(109.0m)/V(692.8m) * Rd(8.09%) * (1-Tc(0.21)))
Discount Rate = 11.89% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 5.88%
[DCF] Terminal Value 69.82% ; FCFF base≈55.8m ; Y1≈63.9m ; Y5≈94.1m
[DCF] Fair Price = 15.00 (EV 960.7m - Net Debt 34.3m = Equity 926.4m / Shares 61.8m; r=11.02% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.48 | # QB: 0
Revenue Correlation: 99.51 | Revenue CAGR: 16.84% | SUE: 3.22 | # QB: 1
EPS current Quarter (2026-07-31): EPS=0.32 | Chg30d=-3.79% | Revisions=-14% | Analysts=10
EPS next Quarter (2026-10-31): EPS=0.35 | Chg30d=-9.37% | Revisions=+14% | Analysts=10
EPS current Year (2027-01-31): EPS=1.30 | Chg30d=-9.99% | Revisions=+14% | GrowthEPS=+0.8% | GrowthRev=+7.2%
EPS next Year (2028-01-31): EPS=1.62 | Chg30d=-6.27% | Revisions=-40% | GrowthEPS=+24.6% | GrowthRev=+4.6%
[Analyst] Revisions Ratio: -40%